During the past decade, Erasmus MC conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Erasmus MC" are "Non-Transfusion-dependent Alpha-Thalassemia" (1 trials), "Non-Transfusion-dependent Beta-Thalassemia" (1 trials), "Transfusion-dependent Alpha-Thalassemia" (1 trials) and "Transfusion-dependent Beta-Thalassemia" (1 trials). Many other conditions were trialed in "Erasmus MC" in a lesser frequency.

Most popular intervention types in "Erasmus MC" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Mitapivat" (2 trials) and "Placebo Matching Mitapivat" (2 trials). Other intervention names were less common.

The vast majority of trials in "Erasmus MC" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Erasmus MC". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Erasmus MC, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Erasmus MC, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".